Edgestream Partners’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,050
Closed -$356K 922
2025
Q4
$356K Buy
+2,050
New +$373K 0.01% 862
2025
Q2
Sell
-8,975
Closed -$1.52M 892
2025
Q1
$1.52M Sell
8,975
-18,717
-68% -$3.07M 0.05% 538
2024
Q4
$4.18M Buy
+27,692
New +$4.31M 0.18% 206
2023
Q2
Sell
-15,773
Closed -$2.23M 751
2023
Q1
$2.23M Buy
+15,773
New +$2.26M 0.25% 122
2022
Q4
Sell
-13,630
Closed -$1.67M 532
2022
Q3
$1.67M Buy
+13,630
New +$1.79M 0.13% 215
2022
Q2
Sell
-5,288
Closed -$724K 532
2022
Q1
$724K Buy
+5,288
New +$737K 0.06% 371
2020
Q4
Sell
-35,772
Closed -$4.1M 368
2020
Q3
$4.1M Buy
+35,772
New +$4.23M 0.26% 129
2019
Q2
Sell
-15,019
Closed -$1.35M 240
2019
Q1
$1.35M Sell
15,019
-11,500
-43% -$997K 0.2% 116
2018
Q4
$2.21M Buy
26,519
+3,899
+17% +$366K 0.39% 87
2018
Q3
$2.44M Buy
22,620
+6,901
+44% +$757K 0.42% 85
2018
Q2
$1.73M Buy
15,719
+5,218
+50% +$544K 0.35% 107
2018
Q1
$1.05M Buy
+10,501
New +$1.08M 0.21% 138
2017
Q3
Sell
-3,406
Closed -$379K 127
2017
Q2
$379K Sell
3,406
-3,363
-50% -$356K 0.14% 100
2017
Q1
$665K Buy
+6,769
New +$645K 0.29% 74

Other funds holding DGX

Edgestream Partners's DGX Position: Q1 2026 in Review

Edgestream Partners sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 2,050 shares — an estimated $356K sold.

Edgestream Partners first reported a position in DGX in Q1 2017 and held it in 14 quarters. The position peaked at $4.18M in Q4 2024. 1,069 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Edgestream Partners reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Edgestream Partners sold 2,050 Quest Diagnostics shares in Q1 2026, an estimated $356K.
  • Edgestream Partners first reported a position in Quest Diagnostics in Q1 2017 and held it in 14 quarters.
  • Edgestream Partners's Quest Diagnostics position peaked at $4.18M in Q4 2024.
  • 1,069 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.